Definitive Contract 75A50126C00004
Award Date 4/6/26
Potential Completion Date 3/10/36
Potential Value $482M
Awardee
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Florham Park, NJ 07932, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $267,582,260 definitive cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, a biopharmaceutical company based in Switzerland. The contract supports the development of antimicrobials for the treatment of resistant fungal and bacterial infections, particularly targeting high-priority pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and multidrug-resistant...
- This is a $135,127,180.73 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Basilea Pharmaceutica International Ltd, doing business as Basilea Pharmaceutica International SA, for the advanced development of the antibiotic ceftobiprole. The contract supports Basilea's work on a new class of antibiotics targeting the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of the...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $220,246,768 Definitive Contract to Aktivax, Inc. to support late-stage clinical development, regulatory approval, and procurement of 2-PAM autoinjectors as a drug-device combination product to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations. This acquisition, which is not set-aside, will allow ASPR's Biomedical...
- Biofactura Inc. received a $65.8 million cost-plus-fixed-fee definitive contract from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the U.S. Department of Health and Human Services. Awarded on September 26, 2019, with an ultimate completion date of March 30, 2029, the contract encompasses preclinical and manufacturing development activities for a medical countermeasure or therapeutic agent. The scope of work includes cell line development, process...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $15,505,000.31 definitive cost-no-fee contract to Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad-spectrum activity against multidrug-resistant Gram-negative ESKAPE pathogens. This work directly responds to a NIAID solicitation for proposals addressing...
- Phlow Corp., a public benefit pharmaceutical manufacturing company, was awarded a cost-plus-fixed-fee definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) under the Department of Health and Human Services to develop and manufacture advanced pharmaceutical active pharmaceutical ingredients (APIs) and related medical countermeasures. The contract, valued at approximately $969.8 million with an ultimate completion date of May 17, 2030, originated from...
- This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- <p>This is a $4,733,100.62 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Achaogen, Inc. for the development of "NOVEL LPXC INHIBITORS FOR THE TREATMENT OF CATEGORY A, B, AND C BACTERIAL INFECTIONS". The contract does not have a set-aside designation. The work is being performed in South San Francisco, California and the contract has an ultimate completion date of June 14, 2022.</p>
- This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...